Stocks · News reference
8-K filing — CytomX Therapeutics, Inc. (CTMX)
Filed: 2026-07-27 AccNo: 0001193125-26-316929 Size: 139 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 27, 2026, 12:05 PM
- Checked
- Jul 27, 2026, 12:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
Read original at benzingaGuggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.
Read original at benzingaCytomX Therapeutics Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $1.418M Miss $12.308M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. The company reported quarterly sales of $1.418 million which
Read original at benzinga